BridgeBio Pharma, Inc. (BBIO) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
30Y Low7.7·High77.8
ROE
N/A
—
5yr avg: N/A
30Y Low-154%·High-139%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BBIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BridgeBio Pharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13.5B | $15.1B | $5.1B | $6.6B | $1.1B | $2.4B | $8.4B | $3.7B | — | — |
| Enterprise Value | $15.7B | $17.2B | $6.2B | $7.9B | $2.5B | $3.7B | $8.5B | $3.4B | — | — |
| P/E Ratio → | -18.18 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 26.88 | 30.05 | 23.01 | 706.43 | 14.47 | 34.54 | 1017.17 | 90.82 | — | — |
| P/B Ratio | — | — | — | — | — | — | 77.77 | 7.74 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BBIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 34.35 | 27.74 | 853.04 | 31.82 | 53.65 | 1034.11 | 84.12 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
BBIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
BridgeBio Pharma, Inc. earns an operating margin of -113.3%. Operating margins have expanded from -6528.8% to -113.3% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.4% | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% | 93.8% | — | — |
| Operating Margin | -113.3% | -113.3% | -267.2% | -6528.8% | -659.6% | -827.1% | -5752.0% | -656.4% | — | — |
| Net Profit Margin | -145.3% | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.1% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -153.7% | -139.1% | — | — |
| ROA | -78.6% | -78.6% | -73.1% | -110.0% | -58.8% | -65.5% | -67.2% | -47.5% | -46.4% | -31.2% |
| ROIC | -524.0% | -524.0% | — | -738.8% | -135.1% | -121.1% | -157.6% | — | — | — |
| ROCE | -80.6% | -80.6% | -101.6% | -134.4% | -74.3% | -77.6% | -80.5% | -53.1% | -70.4% | -49.0% |
BBIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $2.2B ($2.7B total debt minus $570M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 4.60 | 0.19 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | 1.29 | -0.57 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -12.84 | -12.84 | -4.46 | -7.04 | -5.03 | -11.54 | -12.79 | -31.92 | -72.11 | -3370.69 |
BBIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BridgeBio Pharma, Inc.'s current ratio of 2.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 3.32x to 2.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.62 | 2.62 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | 11.36 |
| Quick Ratio | 2.52 | 2.52 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | 11.36 |
| Cash Ratio | 2.04 | 2.04 | 4.41 | 3.02 | 3.89 | 6.19 | 6.35 | 9.04 | 13.39 | 10.76 |
| Asset Turnover | — | 0.54 | 0.24 | 0.02 | 0.12 | 0.07 | 0.01 | 0.06 | — | — |
| Inventory Turnover | 1.06 | 1.06 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 101.37 | 7.77 | 68.70 | 80.28 | 103.40 | — | 25.60 | — | — |
BBIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BridgeBio Pharma, Inc. returns 0.4% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.4% | 0.3% | 0.1% | 0.1% | 0.1% | 8.5% | 0.9% | 0.0% | — | — |
| Total Shareholder Yield | 0.4% | 0.3% | 0.1% | 0.1% | 0.1% | 8.5% | 0.9% | 0.0% | — | — |
| Shares Outstanding | — | $197M | $186M | $163M | $147M | $144M | $118M | $105M | $92M | $92M |
Peer Comparison
Compare BBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BBIOYou | $13B | -18.2 | — | — | 94.4% | -113.3% | — | -524.0% | — |
 KYMR | $8B | -27.0 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARRY | $1B | -11.7 | 13.9 | 16.5 | 21.2% | 6.6% | -19.0% | 9.0% | 5.8 |
 RCUS | $3B | -8.3 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 VRTX | $119B | 30.5 | 23.7 | 37.2 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 ACAD | $4B | 9.6 | 26.3 | 36.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 RARE | $3B | -5.0 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $4B | -43.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $274M | -1.6 | — | — | 100.0% | -245.2% | -198.1% | — | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into BBIO consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BBIO — Frequently Asked Questions
Quick answers to the most common questions about buying BBIO stock.
What is BridgeBio Pharma, Inc.'s P/E ratio?
BridgeBio Pharma, Inc.'s current P/E ratio is -18.2x. This places it at the 50th percentile of its historical range.
Is BBIO stock overvalued?
Based on historical data, BridgeBio Pharma, Inc. is trading at a P/E of -18.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are BridgeBio Pharma, Inc.'s profit margins?
BridgeBio Pharma, Inc. has 94.4% gross margin and -113.3% operating margin.